Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Management of Chronic Kidney Disease Stages 1–3

Slide: 14 of 29

Clinical Bottom Line: Risk for ESRD in Patients With CKD Stages 1–3 Treated With ARBs

In randomized controlled trials of patients with CKD stages 1–3, several treatments reduced the risk of clinical outcomes, but the benefits appeared to be limited to specific CKD subgroups, some of whom already had a clinical indication for the treatment studied. When compared with placebo, ARBs reduced the risk of ESRD by 22 percent but only among patients with overt proteinuria, most of whom had diabetes and hypertension (RR 0.78, 95% CI, 0.67-0.90; 3 trials, n = 4,652; high strength of evidence). ESRD was not significantly reduced in patients with CKD stages 1–3 who did not have proteinuria. Patients with proteinuria, diabetes, and hypertension may benefit from ACEI or ARB treatment.

95% CI = 95-percent confidence interval; ARB = angiotensin II receptor blocker; ARR = absolute risk reduction; CKD = chronic kidney disease; ESRD = end-stage renal disease; RR = risk ratio